SCHEMBL4843388

SCHEMBL4843388

COc1ccc2c(-c3ccc(-c4ccccc4)cc3)nnc(Cl)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.55
PDE4B Q07343 1/20 0.55
PDE4C Q08493 1/20 0.55
PDE4D Q08499 1/20 0.55
NPSR1 Q6W5P4 5/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 4/20 0.47
HTT P42858 2/20 0.47
BCHE P06276 1/20 0.46
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
GPR35 Q9HC97 1/20 0.45
CASR P41180 1/20 0.45
KDM4E B2RXH2 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4845442 0.97 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL6585632 0.91 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4122604 0.91 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4834009 0.88 DHODH (0.48) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4834669 0.87 HTT (0.48) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4833986 0.87 CA9 (0.47) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4840317 0.86 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4840257 0.86 MAPK14 (0.46) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL4842181 0.84 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4843630 0.83 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 PDE4A 1615/4885PDE4B 1845/4885PDE4C 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.